Bispecific T-cell engager: Difference between revisions
From IDWiki
(Created page with "* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target * Used in treating some hematologic malignancies Category:Oncology Category:Biologics") |
No edit summary |
||
Line 1: | Line 1: | ||
+ | == Background == |
||
* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target |
* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target |
||
* Used in treating some hematologic malignancies |
* Used in treating some hematologic malignancies |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | === Adverse Effects === |
||
+ | * Some of the most serious adverse effects include [[cytokine release syndrome]] and [[immune effector cell-associated neurotoxicity syndrome]] |
||
+ | ** Usually within days of first dose |
||
+ | * Causes [[hypogammaglobulinemia]] that can last months to years |
||
+ | * Most patients develop some [[neutropenia]], which can last weeks |
||
+ | * Infections are common, mostly bacterial and viral and occasionally fungal |
||
+ | ** Bacterial pneumonia is most common |
||
+ | ** COVID-19, with prolonged course |
||
+ | ** EBV and CMV, cases of JCV |
||
+ | |||
+ | === Screening === |
||
+ | |||
+ | * Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies |
||
+ | |||
+ | === Antimicrobial Prophylaxis === |
||
+ | |||
+ | * Unclear role for antibiotics and antifungals, in general |
||
+ | * Likely [[PJP]] and [[VZV]] prophylaxis for duration of treatment |
||
[[Category:Oncology]] |
[[Category:Oncology]] |
Latest revision as of 23:16, 25 March 2024
Background
- Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target
- Used in treating some hematologic malignancies
Safety
Adverse Effects
- Some of the most serious adverse effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome
- Usually within days of first dose
- Causes hypogammaglobulinemia that can last months to years
- Most patients develop some neutropenia, which can last weeks
- Infections are common, mostly bacterial and viral and occasionally fungal
- Bacterial pneumonia is most common
- COVID-19, with prolonged course
- EBV and CMV, cases of JCV
Screening
- Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies